BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS
Completed
- Conditions
- Hemophilia A
- Interventions
- Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2014-01-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 405
- Registration Number
- NCT00874926
Patient Characteristics in Daily Radiological Practice of Gadovist® Application (PATRON)
Completed
- Conditions
- Epidemiologic Factors
- Interventions
- Biological: Gadobutrol (Gadovist, BAY86-4875)
- First Posted Date
- 2009-04-02
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3711
- Registration Number
- NCT00874640
Survey on Patient Satisfaction Rate for Mirena Use in Heavy Menstrual Bleeding
- First Posted Date
- 2009-04-02
- Last Posted Date
- 2014-06-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 78
- Registration Number
- NCT00874653
REPEAT - Real-Life Perception of Efficacy, Attitude, Satisfaction and Safety of Levitra Therapy
- First Posted Date
- 2009-04-02
- Last Posted Date
- 2011-11-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 7293
- Registration Number
- NCT00874679
Safety Study Comparing Phenylephrine HCL Extended Release Tablets 30 mg and Placebo (Study CL2007-07)(P07529)(COMPLETED)
Phase 3
Completed
- Conditions
- Blood PressureHuman Experimentation
- Interventions
- First Posted Date
- 2009-04-02
- Last Posted Date
- 2015-03-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 116
- Registration Number
- NCT00874120
US Ovulation Inhibition Study in Obese Women
Phase 2
Completed
- Conditions
- Contraception
- Interventions
- Drug: Ethinylestradiol/Gestodene (BAY86-5016)
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 173
- Registration Number
- NCT00873483
Physical Disability in Patients Treated With Betaferon
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: Interferon-1beta (Betaseron, BAY86-5046)
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 83
- Registration Number
- NCT00873340
PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
Phase 4
Terminated
- Conditions
- Anterior Ischemic Optic Neuropathy
- Interventions
- Drug: Diagnostic procedures
- First Posted Date
- 2009-03-24
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 10
- Registration Number
- NCT00867815
- Locations
- 🇺🇸
Retinal and Ophthalmic Consultants, Houston, Texas, United States
🇺🇸Palm Beach Eye Center, Atlantis, Florida, United States
🇺🇸National Ophthalmic Research Institute, Fort Myers, Florida, United States
Mirena in Idiopathic Menorrhagia
Completed
- Conditions
- Idiopathic Menorrhagia
- Interventions
- First Posted Date
- 2009-03-24
- Last Posted Date
- 2015-02-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1125
- Registration Number
- NCT00868153
Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects
Phase 2
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Drug: Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)Drug: Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2014-12-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 198
- Registration Number
- NCT00865709
© Copyright 2025. All Rights Reserved by MedPath